Li Bing, Ren Shengxiang, Wang Yongsheng, Zhou Caicun, Schmid-Bindert Gerald
Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Tongji University Medical School Cancer Institute, Shanghai, China.
Thorac Cancer. 2013 May;4(2):117-122. doi: 10.1111/j.1759-7714.2012.00173.x.
Recently, differences in tumor biology have been observed between Asian and Caucasian lung cancer patients, resulting in different sensitivities to targeted therapy. To date, all registered third-generation chemotherapeutic agents have been investigated mainly in Caucasians, but little is known whether this data can be transferred to an Asian population. The aim of this study was to provide evidence about the efficacy of chemotherapy in a Chinese population.
Three thousand one hundred patients with advanced non-small-cell lung cancer NSCLC, treated between 2002 and 2009 with a platinum-based doublet first-line chemotherapy, including vinorelbine, gemcitabine, docetaxel or paclitaxel, were included for retrospective survival analysis.
Overall survival (OS) was 12.1 months and progression free survival (PFS) was four months for all patients. No advantage in OS was seen for any of the four compounds. Gemcitabine was associated with a better PFS compared to the other three (P < 0.001). Docetaxel led to higher response rates, but this finding didn't reach statistical significance (P = 0,054). Chinese patients appear to have longer survival times compared to historical data in Caucasians.
Our retrospective analysis suggests, that there is no difference in efficacy of third-generation chemotherapy between Asians and Caucasians.
最近，在亚洲和白种人肺癌患者之间观察到肿瘤生物学存在差异，导致对靶向治疗的敏感性不同。迄今为止，所有已注册的第三代化疗药物主要在白种人中进行了研究，但对于这些数据是否可以应用于亚洲人群却知之甚少。本研究的目的是提供关于化疗在中国人群中疗效的证据。
纳入2002年至2009年间接受含长春瑞滨、吉西他滨、多西他赛或紫杉醇的铂类双联一线化疗的3100例晚期非小细胞肺癌（NSCLC）患者进行回顾性生存分析。
所有患者的总生存期（OS）为12.1个月，无进展生存期（PFS）为4个月。这四种化合物中的任何一种在总生存期方面均未显示出优势。与其他三种药物相比，吉西他滨的无进展生存期更好（P < 0.001）。多西他赛导致更高的缓解率，但这一发现未达到统计学意义（P = 0.054）。与白种人的历史数据相比，中国患者似乎具有更长的生存期。
我们的回顾性分析表明，亚洲人和白种人在第三代化疗疗效方面没有差异。
